14 terminated. 14 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 14 | Terminated 14 |
| Phase 3 | 1 | Terminated 1 |
Follow Proteinuria: new trials by email Literature Review of Proteinuria trials Research Report on Proteinuria
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V Iptacopan (part 1), Iptacopan (part 2), Placebo + standard of care - Lupus Nephritis | Phase 2 | Terminated | Novartis Pharmaceuticals | 81 | 2022-08-10 | 2026-11-12 |
| Safety and Efficacy of AT-1501 in Patients With IgA Nephropathy (IgAN) AT-1501 - IgA Nephropathy, IgAN | Phase 2 | Terminated | Eledon Pharmaceuticals | 24 | 2022-03-21 | 2024-03-26 |
| TreatIng Microalbuminuria Over 24 Weeks in Subjects With or Without Type 2 Diabetes or HYpertension Dapagliflozin 10Mg Tab, Placebo - Albuminuria | Phase 2 | Terminated | University Medical Center Groningen | 9 | 2022-02-03 | 2024-04-17 |
| Optimal Management of HIV Infected Adults at Risk for Kidney Complications in Nigeria Lisinopril, Placebo Oral Tablet - HIV/AIDS, Albuminuria | Phase 2 | Terminated | Vanderbilt University Medical Center | 66 | 2021-04-01 | 2025-06-26 |
| A Study to Evaluate the Safety and Efficacy of AZD5718 in Participants With Proteinuric Chronic Kidney Disease AZD5718, Dapagliflozin 10 mg, Placebo - Chronic Kidney Disease | Phase 2 | Terminated | AstraZeneca | 613 | 2020-10-01 | 2024-12-20 |
| Study of Safety and Efficacy of AVB-S6-500 in Patients With IgA Nephropathy AVB-S6-500 - IgA Nephropathy | Phase 2 | Terminated | Aravive, Inc. | 1 | 2019-11-27 | 2022-02-10 |
| Isosorbide Mononitrate For Anti-Vascular Endothelial Growth Factor (VEGF) Induced Kidney Injury Isosorbide Mononitrate, Placebo oral tablet - Kidney Injury, Proteinuria | Phase 2 | Terminated | The University of Texas Health Science Center, Houston | 9 | 2019-09-26 | 2022-08-03 |
| A Study to Evaluate PF-06730512 in Adults With Focal Segmental Glomerulosclerosis (FSGS) PF-06730512 - Focal Segmental Glomerulosclerosis (FSGS) | Phase 2 | Terminated | Pfizer | 47 | 2018-10-15 | 2024-04-18 |
| A Study of CCX140-B in Subjects With Primary FSGS and Nephrotic Syndrome CCX140-B - Focal Segmental Glomerulosclerosis | Phase 2 | Terminated | Amgen | 5 | 2018-10-01 | 2025-03-17 |
| Efficacy and Safety of Atacicept in IgA Nephropathy Placebo, Atacicept 25 mg, Atacicept 75 mg - IgA Nephropathy | Phase 2 | Terminated | EMD Serono Research & Development Institute, Inc. | 16 | 2017-01-31 | 2021-02-25 |
| Effect of PCSK9-Antibody (Alirocumab) on Dyslipidemia Secondary to Nephrotic Syndrome Alirocumab, Alirocumab placebo, Atorvastatin - Nephrotic Syndrome | Phase 2 | Terminated | Gloria Vega | 3 | 2017-01-01 | 2022-08-19 |
| Preventing Sickle Cell Kidney Disease Losartan - Anemia, Sickle Cell, Sickle Cell Disease | Phase 2 | Terminated | University of Alabama at Birmingham | 1 | 2015-04-01 | 2024-04-03 |
| Rhubarb and Angiotensin Converting Enzyme Inhibitor rhubarb extract, placebo - Diabetic Kidney Disease | Phase 2 | Terminated | Wake Forest University | 8 | 2008-01-01 | 2018-12-13 |
| TNF Blockade With Remicade in Active Lupus Nephritis WHO Class V (TRIAL ) infliximab, placebo - Lupus Erythematosus, Systemic, Lupus Nephritis | Phase 2 / Phase 3 | Terminated | Medical University of Vienna | 1 | 2006-09-01 | 2009-10-05 |
Albuminuria (3) · Glomerulonephritis, IGA (3) · Kidney Diseases (3) · Diabetic Nephropathies (2) · Glomerulosclerosis, Focal Segmental (2) · Hypertension (2) · Lupus Erythematosus, Systemic (2) · Lupus Nephritis (2) · Acquired Immunodeficiency Syndrome (1) · Anemia, Sickle Cell (1) · Diabetes Mellitus (1) · Dyslipidemias (1) · Genetic Predisposition to Disease (1) · Glomerulonephritis (1)
Female Urogenital Diseases (14) · Female Urogenital Diseases and Pregnancy Complications (14) · Male Urogenital Diseases (14) · Pathological Conditions, Signs and Symptoms (14) · Signs and Symptoms (14) · Urination Disorders (14) · Urogenital Diseases (14) · Urologic Diseases (14) · Urological Manifestations (14) · Kidney Diseases (9) · Glomerulonephritis (6) · Immune System Diseases (6) · Nephritis (6) · Autoimmune Diseases (5)
dapagliflozin (2) · AZD5718 (1) · Atorvastatin (1) · CCX140-B (1) · Infliximab (1) · Lisinopril (1) · Losartan (1) · PF-06730512 (1) · Standard of Care (1) · TACI receptor-IgG Fc fragment fusion protein (1) · alirocumab (1) · iptacopan (1) · isosorbide-5-mononitrate (1)
Amgen (1) · Aravive, Inc. (1) · AstraZeneca (1) · EMD Serono Research & Development Institute, Inc. (1) · Eledon Pharmaceuticals (1) · Gloria Vega (1) · Medical University of Vienna (1) · Novartis Pharmaceuticals (1) · Pfizer (1) · The University of Texas Health Science Center, Houston (1) · University Medical Center Groningen (1) · University of Alabama at Birmingham (1) · Vanderbilt University Medical Center (1) · Wake Forest University (1)
United States (10) · Germany (4) · United Kingdom (4) · Japan (3) · Malaysia (3) · Poland (3) · Argentina (2) · Brazil (2) · France (2) · Mexico (2) · Netherlands (2) · Philippines (2) · Spain (2) · Ukraine (2) · Australia (1)
C. William Wester, MD, MPH (1) · Falk Hiepe, MD (1) · Francoise Desir (1) · Gloria L Vega, PhD (1) · Hiddo J. L. Heerspink (1) · Jaya Kala, MD (1) · Jeffrey D Lebensburger, DO, MSPH (1) · John Burkart, MD (1) · Josef S Smolen, MD (1) · Marc Bijl, MD (1) · Martin Aringer, MD (1) · Michael Concepcion, MD (1) · Muktar H. Aliyu, MD, DrPH (1)
PMID 34169203, PMID 34805632, PMID 37528520
2016 (1), 2019 (1), K23HL127100 (1), R21AT002367 (1), U01DK112271 (1)